Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Shares Outstanding (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Shares Outstanding for 4 consecutive years, with $795.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 2.82% to $795.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $795.5 million, a 2.82% increase, with the full-year FY2024 number at $775.7 million, up 10.63% from a year prior.
  • Shares Outstanding was $795.5 million for Q3 2025 at Mereo BioPharma, roughly flat from $795.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $624.9 billion in Q1 2023 to a low of $1.0 million in Q3 2023.
  • A 4-year average of $52.7 billion and a median of $774.7 million in 2024 define the central range for Shares Outstanding.
  • Biggest YoY gain for Shares Outstanding was 77033.52% in 2024; the steepest drop was 99.89% in 2024.
  • Mereo BioPharma's Shares Outstanding stood at $1.5 million in 2021, then skyrocketed by 48009.52% to $701.2 million in 2023, then rose by 10.63% to $775.7 million in 2024, then rose by 2.55% to $795.5 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Shares Outstanding are $795.5 million (Q3 2025), $795.0 million (Q2 2025), and $795.0 million (Q1 2025).